BioArctic is a Swedish biotechnology company and the rights holder for Lecanemab, the world’s first approved treatment for Alzheimer’s disease. Marketed under the brand name Leqembi, Lecanemab is a monoclonal antibody designed to slow disease progression by targeting amyloid-beta plaques in the brain.

Clinical trials have demonstrated that Leqembi reduces cognitive decline by approximately 27% over an 18-month period in patients with early-stage Alzheimer’s disease or mild cognitive impairment. The drug has received regulatory approval in major markets, including the United States, Europe, and Japan, although EU regulators have expressed concerns regarding its safety profile.

Leqembi is distributed by the Japanese multinational pharmaceutical company Eisai in partnership with Biogen. Eisai pays BioArctic a 9% royalty fee for the licensing rights; however, BioArctic has retained exclusive distribution rights in the Nordic region.